Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01897571
Recruitment Status : Active, not recruiting
First Posted : July 12, 2013
Last Update Posted : January 7, 2021
Sponsor:
Information provided by (Responsible Party):
Epizyme, Inc.